Results 31 to 40 of about 2,579,690 (304)

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]

open access: yes, 2014
BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.
Ferguson, J.   +16 more
core   +1 more source

miR-335 Acts as a Tumor Suppressor and Enhances Ionizing Radiation-Induced Tumor Regression by Targeting ROCK1

open access: yesFrontiers in Oncology, 2020
Recent development of integrative therapy against melanoma combines surgery, radiotherapy, targeted therapy, and immunotherapy; however, the clinical outcomes of advanced stage and recurrent melanoma are poor.
Yanfeng Cheng, Peng Shen
doaj   +1 more source

Advances in the Immunobiological Therapies for Advanced Melanoma

open access: yesActas Dermo-Sifiliográficas (English Edition), 2017
Metastatic or locally advanced unresectable melanoma carries a high morbidity and mortality. However, notable advances have been made in recent years in the systemic treatment of this disease, with the appearance of targeted therapy using tyrosine kinase inhibitors that block the mitogen activated protein kinase pathway, and of modern immunotherapy ...
M C, Pérez Gago   +2 more
openaire   +2 more sources

Treatment of Advanced Metastatic Melanoma

open access: yesDermatology Practical & Conceptual, 2021
The introduction in clinical practice of new drug compounds both targeted therapies anti-BRAF and checkpoint inhibitors have largely improved our potential to manage advanced metastatic melanoma patients. This has led to a significant improvement in terms of response rates and particularly in the overall survival (OS).
Quaglino, Pietro   +5 more
openaire   +4 more sources

Identification of new genes associated with melanoma [PDF]

open access: yes, 2011
Purpose: Repeated failures in melanoma therapy made clear that the molecular mechanisms leading to melanoma are still poorly understood. Here, we aim to provide a more comprehensive understanding of the transcriptional profiles and signaling pathways ...
Mauerer, Andreas
core   +1 more source

Metástases cutâneas em melanoma de coróide

open access: yesRevista Brasileira de Oftalmologia, 2011
Metastasis in choroidal melanoma is frequent on advanced diseases, involving mainly the liver, lungs and central nervous system. We report a case of cutaneous metastasis in choroidal melanoma because is an unusual condition, even in advanced disease.
Fabricio Lopes da Fonseca   +1 more
doaj   +1 more source

Penile melanoma

open access: yes, 2021
Penile melanoma is a rare event, responsible for less than 1.4% of penile cancers. In general, it is late diagnosed and the treatment is usually aggressive.
Marcus Maia   +6 more
core   +1 more source

Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review

open access: yesMelanoma Management, 2018
Introduction: Immunotherapies, including checkpoint inhibitors (CIs) such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) inhibitors, are revolutionizing the treatment of advanced melanoma.
Elizabeth S Mearns   +6 more
doaj   +1 more source

Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy

open access: yesCase Reports in Oncology, 2020
Immune checkpoint inhibitors (ICIs) significantly prolong survival in patients with metastatic melanoma but can lead to serious immune-related adverse events.
Yumi Kambayashi   +5 more
doaj   +1 more source

Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data

open access: yesCancer Medicine, 2023
Background In patients with advanced melanoma, immune‐checkpoint inhibitors (ICIs) represent the mainstay for first line treatment. Recently, relatlimab+nivolumab was proposed as a new combination therapy. This review was aimed at summarizing the current
Andrea Ossato   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy